Intrauterine infusion of clinically graded human umbilical cord-derived mesenchymal stem cells for the treatment of poor healing after uterine injury: a phase I clinical trial

Jingrui Huang, Qi Li, Xiaohua Yuan, Qiaoshu Liu, Weishe Zhang, Ping Li, Jingrui Huang, Qi Li, Xiaohua Yuan, Qiaoshu Liu, Weishe Zhang, Ping Li

Abstract

Background: Intrauterine adhesion and cesarean scar diverticulum are the main complications of poor healing after uterine injury. Human umbilical cord MSCs transplantation has been regarded as the most potential treatment in the clinic, the safety and efficacy of which in the clinic, however, remains unclear.

Methods: In this study, ten patients were enrolled: six with intrauterine adhesion and four with cesarean scar diverticulum. All the patients were injected with human umbilical cord MSCs twice into the uterus. Beside the chest X-ray, ECG and abdominal ultrasound, many laboratory tests including blood routine, liver and renal function, ovarian function, tumor biomarkers, and immune function were used to estimate the safe after stem cell transplanted. In addition, the efficacy of stem cell transplanted was shown by the endometrial thickness, the volume of the uterus, and cesarean scar diverticulum based on 3D ultrasound imaging.

Results: We found that all results of these laboratory tests were normal in these enrolled patients before and after cell injection. Meanwhile, the results of the chest X-ray and ECG were also normal in the treatment process. The abdominal ultrasound showed that the size of the left and right kidneys was inconsistent in one patient after cell therapy, while those of other patients were normal. In addition, endometrial thickness, the volume of the uterus, and cesarean scar diverticulum showed an improving tendency, but no significant difference was noted.

Conclusion: In summary, intrauterine injection of clinically graded human umbilical cord MSCs was safe for poor healing after uterus injury. Trial registration NCT03386708. Registered 27 December 2017, https://ichgcp.net/clinical-trials-registry/NCT03386708?cond=CSD&cntry=CN&draw=2&rank=2.

Keywords: Clinical translation; Efficacy; Poor healing after uterus injury; Safety; huUC-MSCs.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study flow diagram
Fig. 2
Fig. 2
Doppler ultrasound imaging from 4 patients with cesarean scar diverticulum before and sixth month after human umbilical cord MSCs
Fig. 3
Fig. 3
Doppler ultrasound imaging from 6 patients with intrauterine adhesion before and sixth month after human umbilical cord MSCs
Fig. 4
Fig. 4
Quantitaive analysis of endometrial thickness (A), volume of uterus (B), volume of cesarean scar diverticulum (C)

References

    1. Leung RK, Lin Y, Liu Y. Recent advances in understandings towards pathogenesis and treatment for intrauterine adhesion and disruptive insights from single-cell analysis. Reprod Sci. 2021;28(7):1812–1826. doi: 10.1007/s43032-020-00343-y.
    1. Al MB, Alrumaih I. Hysteroscopy in the treatment of myometrial scar defect (diverticulum) following cesarean section delivery: a systematic review and meta-analysis. Cureus. 2020;12(11):e11317.
    1. Kou L, Jiang X, Xiao S, Zhao YZ, Yao Q, Chen R. Therapeutic options and drug delivery strategies for the prevention of intrauterine adhesions. J Control Release. 2020;318:25–37. doi: 10.1016/j.jconrel.2019.12.007.
    1. Kangari P, Talaei-Khozani T, Razeghian-Jahromi I, Razmkhah M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. Stem Cell Res Ther. 2020;11(1):492. doi: 10.1186/s13287-020-02001-1.
    1. Esfandyari S, Chugh RM, Park HS, Hobeika E, Ulin M, Al-Hendy A. Mesenchymal stem cells as a bio organ for treatment of female infertility. Cells-Basel. 2020;9(10):2253. doi: 10.3390/cells9102253.
    1. Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal stem/stromal cells for rheumatoid arthritis treatment: an update on clinical applications. Cells-Basel. 2020;9(8):1852. doi: 10.3390/cells9081852.
    1. Shariati A, Nemati R, Sadeghipour Y, et al. Mesenchymal stromal cells (MSCs) for neurodegenerative disease: a promising frontier. Eur J Cell Biol. 2020;99(6):151097. doi: 10.1016/j.ejcb.2020.151097.
    1. Song Y, Zhang J, Xu H, et al. Mesenchymal stem cells in knee osteoarthritis treatment: a systematic review and meta-analysis. J Orthop Translat. 2020;24:121–130. doi: 10.1016/j.jot.2020.03.015.
    1. Le H, Xu W, Zhuang X, Chang F, Wang Y, Ding J. Mesenchymal stem cells for cartilage regeneration. J Tissue Eng. 2020;11:1542294049. doi: 10.1177/2041731420943839.
    1. Murphy MP, Koepke LS, Lopez MT, et al. Articular cartilage regeneration by activated skeletal stem cells. Nat Med. 2020;26(10):1583–1592. doi: 10.1038/s41591-020-1013-2.
    1. Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653–664. doi: 10.1016/j.tips.2020.06.009.
    1. Maqsood M, Kang M, Wu X, Chen J, Teng L, Qiu L. Adult mesenchymal stem cells and their exosomes: sources, characteristics, and application in regenerative medicine. Life Sci. 2020;256:118002. doi: 10.1016/j.lfs.2020.118002.
    1. Hua J, Gong J, Meng H, et al. Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow. Cell Biol Int. 2013;38:198–210. doi: 10.1002/cbin.10188.
    1. Tan Q, Xia D, Ying X. miR-29a in exosomes from bone marrow mesenchymal stem cells inhibit fibrosis during endometrial repair of intrauterine adhesion. Int J Stem Cells. 2020;13(3):414–423. doi: 10.15283/ijsc20049.
    1. Chang QY, Zhang SW, Li PP, Yuan ZW, Tan JC. Safety of menstrual blood-derived stromal cell transplantation in treatment of intrauterine adhesion. World J Stem Cells. 2020;12(5):368–380. doi: 10.4252/wjsc.v12.i5.368.
    1. Santamaria X, Cabanillas S, Cervello I, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod. 2016;31(5):1087–1096. doi: 10.1093/humrep/dew042.
    1. Kim JH, Park M, Paek JY, Lee WS, Song H, Lyu SW. Intrauterine infusion of human platelet-rich plasma improves endometrial regeneration and pregnancy outcomes in a murine model of Asherman's syndrome. Front Physiol. 2020;11:105. doi: 10.3389/fphys.2020.00105.
    1. Jacobson AE, Vesely SK, Haamid F, Christian-Rancy M, O'Brien SH. Mobile application vs paper pictorial blood assessment chart to track menses in young women: a randomized cross-over design. J Pediatr Adolesc Gynecol. 2018;31(2):84–88. doi: 10.1016/j.jpag.2017.09.009.
    1. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172. doi: 10.1038/s41392-020-00286-5.
    1. Lan Y, Liu F, Chang L, et al. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia. BMC Pediatr. 2021;21(1):102. doi: 10.1186/s12887-021-02562-x.
    1. Lamo-Espinosa JM, Blanco JF, Sanchez M, et al. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. J Transl Med. 2020;18(1):356. doi: 10.1186/s12967-020-02530-6.
    1. Li H, Guan Y, Sun B, et al. Role of bone marrow-derived mesenchymal stem cell defects in CD8(+) CD28(-) suppressor T-lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms. Br J Haematol. 2020;191(5):852–862. doi: 10.1111/bjh.16953.
    1. Ding L, Li X, Sun H, et al. Transplantation of bone marrow mesenchymal stem cells on collagen scaffolds for the functional regeneration of injured rat uterus. Biomaterials. 2014;35(18):4888–4900. doi: 10.1016/j.biomaterials.2014.02.046.
    1. Zheng JH, Zhang JK, Kong DS, et al. Quantification of the CM-Dil-labeled human umbilical cord mesenchymal stem cells migrated to the dual injured uterus in SD rat. Stem Cell Res Ther. 2020;11(1):280. doi: 10.1186/s13287-020-01806-4.
    1. Liu Y, Cai J, Luo X, Wen H, Luo Y. Collagen scaffold with human umbilical cord mesenchymal stem cells remarkably improves intrauterine adhesions in a rat model. Gynecol Obstet Invest. 2020;85(3):267–276. doi: 10.1159/000505691.
    1. Zhu H, Pan Y, Jiang Y, Li J, Zhang Y, Zhang S. Activation of the Hippo/TAZ pathway is required for menstrual stem cells to suppress myofibroblast and inhibit transforming growth factor beta signaling in human endometrial stromal cells. Hum Reprod. 2019;34(4):635–645. doi: 10.1093/humrep/dez001.
    1. Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial. Stem Cell Res Ther. 2018;9(1):192. doi: 10.1186/s13287-018-0904-3.
    1. Ma H, Liu M, Li Y, et al. Intrauterine transplantation of autologous menstrual blood stem cells increases endometrial thickness and pregnancy potential in patients with refractory intrauterine adhesion. J Obstet Gynaecol Res. 2020;46(11):2347–2355. doi: 10.1111/jog.14449.
    1. Qiao J, Wang Y, Li X, et al. A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China. Lancet. 2021;397(10293):2497–2536. doi: 10.1016/S0140-6736(20)32708-2.
    1. Benor A, Gay S, DeCherney A. An update on stem cell therapy for Asherman syndrome. J Assist Reprod Genet. 2020;37(7):1511–1529. doi: 10.1007/s10815-020-01801-x.
    1. Zhang L, Li Y, Guan CY, et al. Therapeutic effect of human umbilical cord-derived mesenchymal stem cells on injured rat endometrium during its chronic phase. Stem Cell Res Ther. 2018;9(1):36. doi: 10.1186/s13287-018-0777-5.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅